Literature DB >> 27290716

The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Nalini Vadivelu1, Erika Schermer2, Gopal Kodumudi3, Jack M Berger4.   

Abstract

Opioids are the mainstay for treatment of acute pain and cancer pain, and also have a role in the treatment of chronic non-malignant pain. There has been, however, a growing public health problem stemming from the misuse of opioid analgesics leading to serious consequences. To deter abuse, new formulations of extended-release opioid analgesics and tamper-resistant opioids have recently been developed. The concept of abuse-deterrent extended-release opioids is relatively new and, although abuse may not be completely prevented, the utilization of such abuse-deterrent extended-release opioids could reduce this risk. Extended-release abuse-deterrent opioids have been found to have important clinical applications in cancer, acute pain, and chronic non-malignant pain for analgesia control with decreased incidence of tampering and abuse. In this review, different extended-release formulations of opioids available for clinical applications are presented with descriptions of the formulations, their physical properties, and the clinical studies performed to provide physicians with a better understanding of their uses.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27290716     DOI: 10.1007/s40263-016-0357-0

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  62 in total

1.  12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.

Authors:  Warren Wen; Louise Taber; Shau Yu Lynch; Ellie He; Steven Ripa
Journal:  J Opioid Manag       Date:  2015 Jul-Aug

Review 2.  Extended-release opioids for the management of chronic non-malignant pain.

Authors:  Paul Sloan; Najib Babul
Journal:  Expert Opin Drug Deliv       Date:  2006-07       Impact factor: 6.648

Review 3.  Antagonist models for treating persons with substance use disorders.

Authors:  George E Woody
Journal:  Curr Psychiatry Rep       Date:  2014-10       Impact factor: 5.285

4.  Drug poisoning deaths in the United States, 1980-2008.

Authors:  Margaret Warner; Li Hui Chen; Diane M Makuc; Robert N Anderson; Arialdi M Miniño
Journal:  NCHS Data Brief       Date:  2011-12

5.  Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.

Authors:  Ute Richarz; Sandra Waechter; Rainer Sabatowski; Leszek Szczepanski; Heinrich Binsfeld
Journal:  Pain Pract       Date:  2012-04-18       Impact factor: 3.183

6.  Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study.

Authors:  Derry Ridgway; Maciej Sopata; Arvydas Burneckis; Lillian Jespersen; Christine Andersen
Journal:  J Pain Symptom Manage       Date:  2010-04       Impact factor: 3.612

7.  Recent developments toward the safer use of opioids, with a focus on hydrocodone.

Authors:  Jordan R Covvey
Journal:  Res Social Adm Pharm       Date:  2015-02-13

8.  Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsules.

Authors:  Murad R Melhem; Christopher M Rubino; Stephen J Farr; Cynthia Y Robinson
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

9.  A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Authors:  Winfried Meissner; Petra Leyendecker; Stefan Mueller-Lissner; Joachim Nadstawek; Michael Hopp; Christian Ruckes; Stefan Wirz; Wolfgang Fleischer; Karen Reimer
Journal:  Eur J Pain       Date:  2008-08-31       Impact factor: 3.931

10.  Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study.

Authors:  Seong Hoon Shin; Ho Sup Lee; Yang Soo Kim; Young Jin Choi; Sung Hyun Kim; Hyuk Chan Kwon; Sung Yong Oh; Jung Hun Kang; Chang Hak Sohn; Sang Min Lee; Jin Ho Baek; Young Joo Min; Choongrak Kim; Joo Seop Chung
Journal:  Cancer Res Treat       Date:  2014-07-21       Impact factor: 4.679

View more
  4 in total

Review 1.  Opioid Prescribing in an Opioid Crisis: What Basic Skills Should an Oncologist Have Regarding Opioid Therapy?

Authors:  Joseph Arthur; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

Review 2.  Oxycodone DETERx® ER Capsules: A Review in Severe, Chronic Pain.

Authors:  Yvette N Lamb; Karly P Garnock-Jones; Susan J Keam
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 3.  Management of Patients on Abuse-Deterrent Opioids in the Ambulatory Surgery Setting.

Authors:  Nalini Vadivelu; Daniel Chang; Leandro Lumermann; Thomas Suchy; Matthew M Burg; Manuel L Fontes
Journal:  Curr Pain Headache Rep       Date:  2017-02

Review 4.  Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic.

Authors:  Amie L Severino; Arash Shadfar; Joshua K Hakimian; Oliver Crane; Ganeev Singh; Keith Heinzerling; Wendy M Walwyn
Journal:  Front Psychiatry       Date:  2018-04-23       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.